Literature DB >> 10704896

Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity.

G González-Martín1, C Figueroa, I Merino, A Osuna.   

Abstract

The activity of allopurinol-loaded polyethylcyanoacrylate nanoparticles against Trypanosoma cruzi was compared to that of free allopurinol using in vitro cultures of epimastigotes. Ethylcyanoacrylate nanoparticles were prepared by an emulsion polymerization process, and formulations containing different concentrations of allopurinol, polyethylcyanoacrylate and surfactants were investigated and analyzed in size and amount of drug entrapped. The nanoparticles obtained were less than 200 nm in size, as measured by electron microscopy and cytometry. The peak amount of allopurinol entrapped in the nanoparticles was 62.8+/-1.9 microg mg(-1) of nanoparticles using 400 microl of polyethylcyanoacrylate, 200 microl of surfactant (Tween 20) and 20 mg of allopurinol in 50 ml of polymerization medium and the association efficiency was 100.7%. After 6 h of incubation at pH 7.4 the release of allopurinol from the nanoparticles was 7.4%, while at pH 1.2 only 3.1% was released after 4-6 h (t=42.8, P<0.0001). The in vitro studies, using cultures of T. cruzi epimastigotes, demonstrated considerable increases in the trypanocidal activity of the allopurinol-loaded nanoparticles in comparison with a standard solution of allopurinol (91.5 vs. 45.9%) at an allopurinol concentration of 16.7 microg ml(-1). In addition, it was shown that the unloaded nanoparticles, by mechanisms not completely elucidated, had a trypanocidal activity similar to that of standard solutions of allopurinol. To study cytotoxicity, increasing concentrations of unloaded nanoparticles were incubated on vero-line cell cultures. The concentration that killed 50% cells was 200 microg ml(-1), four times higher than that necessary to kill 50% of T. cruzi. It is concluded that the polyethylcyanoacrylate nanoparticles constitute a good carrier of drugs against the T. cruzi. The allopurinol loaded-nanoparticles significantly increased the trypanocidal activity in comparison to the free drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704896     DOI: 10.1016/s0939-6411(99)00076-4

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

Review 1.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.

Authors:  O Kayser; C Olbrich; S L Croft; A F Kiderlen
Journal:  Parasitol Res       Date:  2002-12-11       Impact factor: 2.289

2.  Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease.

Authors:  Renata Tupinambá Branquinho; Vanessa Carla Furtado Mosqueira; Jaquelline Carla Valamiel de Oliveira-Silva; Marianne Rocha Simões-Silva; Dênia Antunes Saúde-Guimarães; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

Review 3.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01

Review 4.  Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.

Authors:  Eliana B Souto; João Dias-Ferreira; Sara A Craveiro; Patrícia Severino; Elena Sanchez-Lopez; Maria L Garcia; Amélia M Silva; Selma B Souto; Sheefali Mahant
Journal:  Pathogens       Date:  2019-08-01

Review 5.  Advances in nanocarriers as drug delivery systems in Chagas disease.

Authors:  Christian Quijia Quezada; Clênia S Azevedo; Sébastien Charneau; Jaime M Santana; Marlus Chorilli; Marcella B Carneiro; Izabela Marques Dourado Bastos
Journal:  Int J Nanomedicine       Date:  2019-08-09

6.  Topical Allopurinol-Loaded Nanostructured Lipid Carriers: A Novel Approach for Wound Healing Management.

Authors:  Carla Varrica; Manuela Carvalheiro; Catarina Faria-Silva; Carla Eleutério; Giuseppina Sandri; Sandra Simões
Journal:  Bioengineering (Basel)       Date:  2021-11-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.